

****Published September 2024****

MarketVIEW: Dengue endemic vaccines (CAT: VAMV025)

Product Name	:	MarketVIEW: Dengue endemic vaccines
Description	:	Global vaccine commercial opportunity assessment
Contents	:	Executive presentation (>375 slides.pdf) + MS forecast model(s) (.xls)
Therapeutic Area	:	Dengue endemic vaccines
Publication date	:	September 2024
Catalogue No	:	VAMV025

Background

Dengue fever (DF) is a mosquito-borne disease (*Aedes*) caused by single-stranded RNA viruses of the family *flaviviridae*. DF has a wide spectrum of symptoms ranging from a mild febrile illness to severe outcomes such as hospitalization and death as observed in dengue haemorrhagic fever (DHF) and dengue shock syndrome (DSS). Published estimates indicate that **390m** dengue infections occur each year of which **20-30%** are symptomatic (any severity) and **17-49K** deaths occur. It is estimated that **3.9bn** of the world's population (~90 countries) are thought to be at risk from dengue infection, mainly urban dwellers in tropical and sub-tropical countries. Importantly, most of the estimated deaths per year are in children (< 15yrs). No specific treatment is available.

Dengue cases are at a record high in **2024** with **~11.5m** probable cases reported (as of 21st August 2024) and ~7K deaths. **Brazil** is particularly affected prompting the health authorities to begin mass vaccination campaigns with Takeda Vaccines' **Qdenga®** (TAK-003) in priority age groups in certain high-transmission municipalities. **Qdenga®** which is undergoing global registrations is expected to face competition in the PAHO region from Instituto Butantan's single-dose vaccine (Butantan-DV, NIAID-licensed) which has also met its endpoint in a large Phase 3 study. Other dengue vaccines such as **Merck & Co's V181**, **Panacea's DengiALL** and KM Biologics/Meiji KD-383 + others are in development.

This **MarketVIEW** product consists of a detailed Executive presentation (>375 slides) and a comprehensive MS-Excel forecast model (250 worksheets) which forecast the potential commercial value of dengue endemic vaccine(s) by competitor across 55 endemic markets to 2036. The model(s) contain value (\$ m) and volume (mio doses) predictions (public and private sector) in adjustable age segments e.g., >4 yrs, >19 yrs. LO, BASE and HI forecast scenarios include potential demand from selected country mass campaigns, routine inclusion and expected approvals from **2022** onwards. An intra-state or region roll-out analysis is also included for Brazil and The Philippines. New case studies to guide forecast uptake projections are included for **2024**.

Methodology

VacZine Analytics has closely monitored all significant source material pertaining to Dengue endemic vaccines in each respective market. Source materials used are academic literature articles, government websites, medical bodies and associations, conference proceedings, social media etc. Previously published research by **VacZine Analytics** in the field of viral pathogens has also been utilised.

PRODUCT CONTENTS:

Published September 2024 (CAT No: VAMV025)

****This product is a [summary presentation \(.pdf\)](#), [an MS-workbook \(.xls\)](#)

Contents – Summary presentation (.pdf)



Contents

Author's notes

Executive summary

[SECTION 1] Commercial model: key outputs

[SECTIONS 2-5] Dengue: disease epidemiology – per region, major transmission countries

[SECTION 6] Dengue: economic burden, impact of climate change

[SECTION 7] Dengue: new vaccines – vaccinology. R&D update

[SECTION 8] Dengue vaccines: current/previous licensed products, clinical data, status

[SECTION 9] Dengue vaccines: current market, deployment and future implementation

[SECTION 10] Dengue vaccines: new 2024 forecast, changes since September 2021 analysis, assumptions

Appendix: back-up and source material

References/bibliography

About **VacZine Analytics**

Disclaimer

SNAPSHOT

PAGES: >375 slides fully referenced/sourced. Available in .pdf form

Contents – MS-Excel workbook (.xls)



United States [Adjustable pediatric and adult target populations, public and private sector]

6 Island nations

PAHO region

22 countries

Brazil [sub national]

SEA region

11 countries **SNAPSHOT**

WPR region

16 countries

Philippines [sub national]

PRODUCT COST:

VacZine Analytics will grant a [enter region] license to [enter client name], for the price of:

- FULL PRODUCT [.pdf presentation + MS-Excel] - USD **enquire**/ GBP **enquire**# (Global license)*

*A region is North America, Europe, or ROW. Global is all 3 regions

For orders in the UK, VAT at 20% will be added to final invoice total

- *indicative prevailing rate will be applied on date of transaction*

Licenses are non-exclusive and non-transferable to 3rd parties

HOW TO ORDER:

To order please contact your region account manager or order direct at orders@vaczine-analytics.com This report can also be purchased on-line. Please review the **TERMS and CONDITIONS** of purchase.



VacZine Analytics ® is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

VacZine Analytics ® and the “**spiral logo**” are UK Registered Trademarks, 2009



BIBLIOGRAPHY

~250 References – available upon request





TERMS and CONDITIONS:

VacZine Analytics – a trading division of Assay Advantage Ltd UK Company Number: 5807728 (Herein referred to as “The Company”). (Herein [enter client name] to as “The Client”).

1. All Rights Reserved. This finished research product is a licensed product. It may not be reproduced, stored in a retrieval system, or transmitted in any form without the written permission of the Company **VacZine Analytics** (of division of Assay Advantage Ltd).
2. The license granted by the Company to the Client will be non-exclusive, non-transferable and should only be used for the Client business purposes at the agreed Client sites/location in accordance with this agreement. The Client will have no ownership rights over the research product.
3. Invoicing will **100%** after submission of the deliverables (.pdf) and (.xls) to the Client.
4. If not purchased online invoices are payable within **thirty days** of the invoice date.
5. All proposals are quoted in **\$USD dollars or £GBP or €euro** and invoices are to be settled in the same currency.
6. The Company agrees not to disclose to any third-party confidential information acquired while providing the research product listed without the prior written consent of the Client. Exception occurs when the information is already in the public domain or when disclosure is necessary to help the Company's employees and agents with the performance of the Company's obligations to achieve satisfactory completion of the project and approved in writing by the Client.
7. Force Majeure: The Company will not be liable for any delay or failure to perform any obligation under this Agreement insofar as the performance of such obligation is prevented by an event beyond our reasonable control, included by not limited to, earthquake, fire, flood or any other natural disaster including pandemic, labour dispute, riot, revolution, terrorism, acts of restraint of government or regulatory authorities, failure of computer equipment and failure or delay of sources from which data is obtained.
8. Please also refer to Master **TERMS and CONDITIONS** available upon request.

VacZine Analytics

A division of Assay Advantage Ltd
Warren (Carlton) House
Bells Hill
Bishops Stortford
Herts
CM23 2NN
United Kingdom
Tel: +44 (0) 1279 927049
E-mail: info@vacZine-analytics.com

About VacZine Analytics:

VacZine Analytics is an established strategic research agency based in the United Kingdom. Its aim is to provide disease and commercial analysis for the vaccine industry and help build the case for developing new vaccines and biologics.

For more information, please visit our website www.vacZine-analytics.com

VacZine Analytics ® is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

VacZine Analytics ® and "the spiral logo" are UK Registered Trademarks, 2009



Since 2007



VacZine Analytics®
Bringing life to vaccine strategy...



Bringing life to vaccine strategy...

www.vaccine-analytics.com

Carlton House, Bells Hill, Bishops Stortford, Herts CM23 2NN, United Kingdom **Tel.** +44(0)1279 927049 **e-mail:** info@vaccine-analytics.com

